Thus, the authors conclude that patients with SPMS have a high expression of CCR2, a chemokine receptor associated with TH2 profile, whereas patients with RRMS preferentially display T cells with CCR5 expression and TH1 profile. Here, CCR2 is linked to secondary progressive multiple sclerosis.